These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 30604312)

  • 1. Inhibitor development, safety and efficacy of Advate
    Fukutake K; Taki M; Matsushita T; Nogami K; Shima M; Yoshioka A; Takamatsu J; Uchikawa H; Takagi H; Arai M; Engl W; Shirahata A
    Int J Hematol; 2019 Mar; 109(3):336-345. PubMed ID: 30604312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitor development, safety, and efficacy of Advate
    Taki M; Fukutake K; Matsushita T; Nogami K; Shima M; Yoshioka A; Takamatsu J; Arai M; Takagi H; Uchikawa H; Engl W; Shirahata A
    Int J Hematol; 2019 Jan; 109(1):70-78. PubMed ID: 30043332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative safety and hemostatic efficacy of Advate
    Nogami K; Takedani H; Shima M; Yoshioka A; Matsushita T; Takamatsu J; Taki M; Fukutake K; Uchikawa H; Takagi H; Arai M; Engl W; Shirahata A
    Int J Hematol; 2018 Jul; 108(1):22-29. PubMed ID: 29594923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
    Zhao Y; Hu Y; Jin J; Zhao X; Wang X; Wu R; Wu D; Yang R; Yang F; Hu Q; Wang J; Fang H; Engl W
    Clin Appl Thromb Hemost; 2021; 27():1076029621989811. PubMed ID: 33587652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice.
    Oldenburg J; Goudemand J; Valentino L; Richards M; Luu H; Kriukov A; Gajek H; Spotts G; Ewenstein B
    Haemophilia; 2010 Nov; 16(6):866-77. PubMed ID: 20579113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of B-domain Deleted Third Generation Recombinant Factor VIII (GreenGene F™) in Korean Patients with Hemophilia A: Data from a Post-marketing Surveillance Study.
    Kim SK; Yoo KY; Lee KS; Hwang T; Choi YM; Choi EJ; Park SK
    J Korean Med Sci; 2018 Jan; 33(1):e5. PubMed ID: 29215814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.
    Smith MP; Giangrande P; Pollman H; Littlewood R; Kollmer C; Feingold J;
    Haemophilia; 2005 Sep; 11(5):444-51. PubMed ID: 16128886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
    Chowdary P; Mullins ES; Konkle BA; McGuinn C; Park YS; Stasyshyn O; Zulfikar B; Engl W; Tangada S
    Haemophilia; 2020 Jul; 26(4):e168-e178. PubMed ID: 32597029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of full-length pegylated recombinant factor VIII with extended half-life in previously treated patients with hemophilia A: comparison of data between the general and Japanese study populations.
    Nogami K; Shima M; Fukutake K; Fujii T; Taki M; Matsushita T; Higasa S; Sato T; Sakai M; Arai M; Uchikawa H; Engl W; Abbuehl B; Konkle BA
    Int J Hematol; 2017 Nov; 106(5):704-710. PubMed ID: 28550352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octocog alfa (Advate®): a guide to its use in hemophilia A.
    Keating GM; Dhillon S
    BioDrugs; 2012 Aug; 26(4):269-73. PubMed ID: 22759264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and immunogenicity of rurioctocog alfa pegol for prophylactic treatment in previously treated patients with severe hemophilia A: a systematic review and meta-analysis of clinical trials.
    Witarto BS; Visuddho V; Witarto AP; Sutanto H; Wiratama BS; Wungu CDK
    F1000Res; 2021; 10():1049. PubMed ID: 35136579
    [No Abstract]   [Full Text] [Related]  

  • 12. Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM.
    Iorio A; Marcucci M; Cheng J; Oldenburg J; Schoenig-Diesing C; Matovinovic E; Romanov V; Thabane L
    Haemophilia; 2014 Nov; 20(6):777-83. PubMed ID: 25039809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.
    Musso R; Santagostino E; Faradji A; Iorio A; van der Meer J; Ingerslev J; Lambert T; Maas-Enriquez M; Gorina E;
    Thromb Haemost; 2008 Jan; 99(1):52-8. PubMed ID: 18217134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study.
    Pollmann H; Klamroth R; Vidovic N; Kriukov AY; Epstein J; Abraham I; Spotts G; Oldenburg J
    Ann Hematol; 2013 May; 92(5):689-98. PubMed ID: 23324986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study.
    Khair K; Mazzucconi MG; Parra R; Santagostino E; Tsakiris DA; Hermans C; Oldenburg J; Spotts G; Steinitz-Trost K; Gringeri A
    Haemophilia; 2018 Jan; 24(1):85-96. PubMed ID: 29044825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A.
    Dhillon S
    Drugs; 2012 May; 72(7):987-1007. PubMed ID: 22564135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
    Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
    Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.
    Konkle BA; Stasyshyn O; Chowdary P; Bevan DH; Mant T; Shima M; Engl W; Dyck-Jones J; Fuerlinger M; Patrone L; Ewenstein B; Abbuehl B
    Blood; 2015 Aug; 126(9):1078-85. PubMed ID: 26157075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study.
    Holstein K; Liu X; Smith A; Knöbl P; Klamroth R; Geisen U; Eichler H; Miesbach W; Tiede A
    Blood; 2020 Jul; 136(3):279-287. PubMed ID: 32268359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity, safety, and efficacy of rurioctocog alfa pegol in previously untreated patients with severe hemophilia A: interim results from a phase 3, prospective, multicenter, open-label study.
    Sidonio RF; Thompson AA; Peyvandi F; Stasyshyn O; Yeoh SL; Sosothikul D; Antmen AB; Maggiore C; Engl W; Ewenstein B; Tangada S
    Expert Rev Hematol; 2023; 16(10):793-801. PubMed ID: 37646148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.